Risedronate Reduces Some Bone Loss in Patients with ALL/LL Receiving High-Dose …Monthly Prescribing ReferenceCorticosteroids are a well-known cause of osteoporosis. Although virtually no information on osteoporosis in the adult ALL population exists,…
HemOncTodayEverolimus plus paclitaxel failed to improve pathological complete response rateHemOncTodaySAN ANTONIO — Adding everolimus to 12 weeks of paclitaxel as neoadjuvant therapy did not improve the rate of pathological complete response in patie…
Brandeis UniversityResearchers discover a mechanism of drug resistanceBrandeis UniversityPenicillium molds are best known for making penicillin, but also produce the not-so-famous mycophenolic acid, a billion-dollar drug used to ward off organ rejectio…
USA TodayBreast Cancer Survival Up With Everolimus + ExemestaneMonthly Prescribing Reference(HealthDay News) – Everolimus plus exemestane improves progression-free survival (PFS) for postmenopausal women with hormone-receptor (HR)-positive breast cance…
CBC.camTOR inhibitors gaining favor for breast cancer treatmentEmory Health Now (blog)Ruth O'Regan, MD, director of the Translational Breast Cancer Research Program at Winship Cancer Institute, has led clinical studies of everolimus in breast cance…
Two drugs appear to delay cancer progressionNews ChiefBoth drugs, pertuzumab from Genentech and everolimus from Novartis, also showed signs that they could prolong lives, though researchers said it was too early to say that definitively. Results of the…
Stress affects pregnancy outcomes, research revealsInternational Federation of Gynecology and ObstetricsThe administration of corticosteroids in infants born at 23 to 25 weeks' gestation is associated with improved outcomes, new maternal and newbor…
abc13.comSABCS: Updated BOLERO-2 Findings Confirm Efficacy of Everolimus Plus ExemestaneCancer NetworkSAN ANTONIO—Updated findings from the pivotal phase III Breast Cancer Trials of Oral Everolimus (BOLERO-2) study confirm dramatic improvement in pro…
abc13.comWomen With Previously Treated Advanced Breast Cancer Benefit From Addition Of …Medical News TodayThe mammalian target of rapamycin (mTOR) inhibitor everolimus given with the aromatase inhibitor exemestane markedly boosts progression-free sur…
HemOncTodayEverolimus improved PFS in patients with metastatic, ER-positive breast cancerHemOncTodaySAN ANTONIO — Adding everolimus to exemestane in postmenopausal patients with ER-positive advanced breast cancer improved PFS, according to research p…